Brooks Laboratories share news, announcements and annual reports
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Brooks Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹60.56down ₹3.28 (5.14%)BSE ₹60.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹63.84.
30 Oct: open ₹65.80, high ₹66.00, low ₹59.70
52-week range of traded prices to 30 Oct 2026
₹36.30Low, 30 Mar 2026₹116.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹178 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.45
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,79557.7% delivered
Brooks Laboratories board and management
52 filed, newest first. Page 1 of 2.
Sep 2026
16 Sep · Management
Jul 2026
May 2026
Oct 2025
Sep 2025
Dec 2024
Oct 2024
Sep 2024
19 Sep · Management
Aug 2024
14 Aug · Management
7 Aug · Management
7 Aug · Management
Aug 2023
23 Aug · Management
23 Aug · Management
Jul 2023
Nov 2022
May 2022
Nov 2021
Sep 2021
Sep 2020
May 2020
Sep 2019
25 Sep · Management
Aug 2019
26 Aug · Management
Dec 2015
May 2015
Nov 2014
Sep 2014
Aug 2014
May 2014
Oct 2013
3 Oct · Management
Resolution was passed by circulation effected on September 28, 2013 whereby Mr. Deepak Mahajan was appointed as Additional Independent Director with effect from September 28, 2013. Further, he has also been appointed as a member of Shareholders Grievances Committee and Remuneration Committee of the Board of Directors of the Company.
May 2013
27 May · Management
Resolution was passed by circulation effected on 22.05.2013 whereby Mr. Bhaskar Sharma has been appointed as Additional Independent Director with effect from 22.05.2013. Further, he has also been appointed as a member of Audit Committee, Shareholders Grievances Committee and Remuneration Committee of the Board of Directors of the Company.
Apr 2013
3 Apr · Management
Following directors have resigned as Independent Director of the Company: (1) Mr. Anil Khanna; (2) Mr. Harsh Bhalla. The Board accepted their resignation in its meeting held on April 02, 2013 with effect from the date of the meeting.
Dec 2012
31 Dec · Management
Resolution was passed by circulation effected on October 16, 2012 whereby the resignation of Mr. Dinesh Puri from the post of Independent Director of the Company was accepted with immediate effect.